Biotechnology, Pharmaceutical and Life Science Reports and Courses

Main Pages

Best Selling Products

BioNewsCast Press Release Distribution Service

Vaccine Technology 2009 Conference

Veterinary Diagnostics Markets

Practical Guide to Finding Partners in Pharma & Biotech, 2nd edition

Royalty Financing Agreements in Pharma, Biotech and Diagnostics

New Products

Attention Deficit Hyperactivity Disorder: Diagnosis and Treatment

Bioinformatics Market Potential

Biotechnology in the European Union; Trends, Investing & Country Profiles

China Pharmaceutical Industry: Analysis and Market Trends

European Generic Drug Market Potential

Global Biotechnology Markets Trends

Strategic Alliances in World Pharma and Biotech Markets

Understanding China's Chemical Industry

Understanding Genomics and Global Health Impacts

Understanding Pharmacogenomics

BioPortfolio | BioInformant Reports

Capitalizing on Opportunities in <p></p>Cord Blood Industry Growth

Capitalizing on Opportunities in
Cord Blood Industry Growth
Overview: Over the past 12 months, the cord blood banking industry has expanded through double digit growth, due to new entrants in the cord blood banking industry as well as revenue growth at existing operations. Deeper analysis reveals that of existing cord blood banks, most fall into one of two “camps,” either experiencing flat-line growth (less than 3% per annum) or substantively building revenue (17% or more per annum).

Choices in Cord Blood Banking: Factors Influencing Parental Decision-Making
# Rates of awareness by gender, income, geographic location, and education

# Sources through which expectant parents learn of cord blood preservation

# Factors influencing private vs. public storage of cord blood

# Price sensitivity and quality expectations

# Approaches for communicating with expectant parents

# Key factors influencing the decision to store cord blood

# Parental responsiveness to health statistics

# Trends in cord blood banking

# Competitive analysis of the cord blood banking industry

Opportunities in Human Embryonic Stem Cell <p></p>(hESC) Products

Opportunities in Human Embryonic Stem Cell
(hESC) Products
Human embryonic stem cells (hESCs) are stem cells derived from the inner cell mass of a blastocyst, which is a stage reach 4-5 days post fertilization. They are the most pluripotent of all stem cell types and can develop into over 200 different cell types of the human body, providing tremendous therapeutic potential.

Human ESCs were first derived from mouse embryos in 1981 by Martin Evans and Matthew Kaufman, and independently by Gail R. Martin. In 1995, the first successful culturing of primate embryonic stem cells occurred at the University of Wisconsin-Madison. Another breakthrough followed at the University of Wisconsin-Madison in November 1998 when a group led by Dr. James Thomson developed a technique to isolate and grow human embryonic stem cells derived from human blastocysts.

Neuronal Stem & Progenitors Cells
Overview: Neurogenesis is the process by which neurons are created. This process is most active during pre-natal development when neurogenesis is responsible for populating the growing brain. Neural stem cells (NSCs) are the self-renewing, multipotent cells that differentiate into the main phenotypes of the nervous system. These cell types include neurons, astrocytes, and oligodendrocytes. Neural progenitor cells (NPCs) are the progeny of stem cell division that normally undergo a limited number of replication cycles in vivo.

Mesenchymal Stem Cells, Advances and Applications
Mesenchymal stem cells (MSCs) are multipotent stem cells that can differentiate into a variety of cell types, including osteoblasts, chondrocytes, myocytes, adipocytes, beta-pancreatic islets cells, and potentially, neuronal cells.

Pharmacodynamic Assays Market Report
Pharmacodynamic assays are assays that provide methods for quickly and easily screening cell samples for a pharmacodynamic effect to a drug or test agent. These assays inform drug development decisions by providing evidence of drug action on molecular targets.

Stem Cell Research Products: Opportunities Tools and Technologies
* What are novel stem cells research products that can be developed?

* What stem cells types are most frequently used by research scientists?

* Which species of stem cells do scientists prefer and what are the factors driving this preference (access, pricing, funding, handling advantages)?

* What are the most frequently used stem cell markers?

* What are the most common research applications, and how do they differ by segment (academic, industrial, and government)?

* Who are the leading suppliers of stem cell products?

* What stem cell product categories are already available in the marketplace?

* What are current grant, patent, and scientific publication rate trends?

* What are the major funding sources, trends, and dollar values, for domestic and international researchers?

* What is the size of the stem cell research products marketplace and how fast is it growing?

* What are communication strategies for accessing the marketplace?

Poly(ADP-ribose) polymerase (PARP) Research Products
Poly(ADP-ribose) polymerases (PARPs) are a superfamily of 18 proteins, of which PARP-1 is the best characterized. PARPs are enzymes that are activated by DNA breaks to facilitate DNA repair

Currently, there is a great deal of research being done on PARP, because its activity is linked to serious disease conditions, including cancer, ischemia, diabetes, arthritis, inflammatory bowel disease, and septic shock. Of greatest therapeutical interest are PARP-1 inhibitors, as they exert a duel effect of inhibiting cell death and reducing inflammation. Indeed, PARP inhibitors have been shown to be effective as radiation-sensitizing agents and appear promising in the treatment of conditions involving oxidative stress. Additionally, quantification of PARP activity and identification of abnormal patterns of PARP degradation by proteases might have utility in the diagnosis various conditions.

BioPortfolio uses RBS Worldpay Secure Server for credit card transactions